Table 1 Investigation results
From: PRKAR1A-negative familial Cushing’s syndrome: two case reports
Investigations | Patient 1 | Patient 2 | Reference range |
|---|---|---|---|
Liddle’s test | N/A | 24-h UFC (predexamethasone) 3923 nmol/L | 58–805 nmol/L |
24-h UFC (postdexamethasone) 4168 nmol/L | |||
HbA1c (NGSP) | 5.1 % | 5.1 % | <6.5 % |
fT4 | 12.9 pmol/L | 16.7 pmol/L | 11–23 pmol/L |
TSH | 0.67 mIU/L | 0.72 mIU/L | 0.5–5.5 mIU/L |
IGF-1 | 268 ng/ml | 282 ng/ml | 116–350 ng/ml (patient 1) |
193–731 ng/ml (patient 2) | |||
GH | 2.3 ng/ml | 0.2 ng/ml | 0.0–3.0 ng/ml |
LH | 1.4 IU/L | 5.8 IU/L | Follicular phase 1.9–12.5 IU/L |
Midcycle 8.7–76.3 IU/L | |||
Luteal phase 0.5–16.9 IU/L | |||
Male 1.5–9.3 IU/L | |||
FSH | 2.2 IU/L | 8.8 IU/L | Follicular phase 2.5–10.2 IU/L |
Midcycle 3.4–33.4 IU/L | |||
Luteal 1.5–9.1 IU/L | |||
Male 1.4–18.1 IU/L | |||
Testosterone | 3.4 nmol/L | 13.0 nmol/L | Female 0.5–2.6 nmol/L |
Male 9.3–23.0 nmol/L | |||
DHEA-S | 0.07 μg/dl | 0.04 μg/dl | Female 0.02–0.30 μg/dl |
Male 0.10–0.40 μg/dl | |||
Estradiol | 153 pg/ml | N/A | Follicular phase 20–144 pg/ml |
Midcycle 64–357 pg/ml | |||
Luteal phase 56–214 pg/ml | |||
Prolactin | 123 mIU/L | 127 mIU/L | Female 59–619 mIU/L |
Male 44–373 mIU/L | |||
Thyroid US | Normal | Well-defined right thyroid cystic nodule with soft tissue component (1.1 × 1.0 × 1.4 cm), increased peripheral vascularity |